Evidence map›Paper›PMID 41656812›Full record

ArticleZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences2025

Exploration of safety indicators for radiotherapy in hepatocellular carcinoma: A real-world study.

Xueyi Xie, Xi Zhang, Honghua Peng, Jun Zhang, Yuliang Pan, Zhen Zhang, Qiao Jin, Peiguo Cao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xueyi XieDepartment of Oncology, Third Xiangya Hospital, Central South University, Changsha 410013, China. doctorxxy1995@163.com.
Xi ZhangDepartment of Oncology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Honghua PengDepartment of Oncology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Jun ZhangDepartment of Oncology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Yuliang PanDepartment of Oncology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Zhen ZhangDepartment of Oncology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Qiao JinDepartment of Oncology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Peiguo CaoDepartment of Oncology, Third Xiangya Hospital, Central South University, Changsha 410013, China. xy3caopg@csu.edu.cn.

Funding

the Chen Xiaoping Foundation for the Development of Science and Technology of Hubei Province CXPJJH12000001-2020216the National Natural Science Foundation 81872473the Wu Jieping Medical Foundation 320.6750.19094-30This is an open access article under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International CC BY-NC-ND 4.0 and //creativecommons.org/licenses/by-nc-nd/4.0/
6 · The paper itself

Abstract

objectivesHepatocellular carcinoma (HCC) is the most common pathological subtype of primary liver cancer and is associated with high incidence and mortality. External beam radiation therapy (EBRT) is a widely used local treatment modality for HCC across different disease stages. In the era of precision radiotherapy, standardized safety evaluation indicators for HCC radiotherapy remain lacking. Normal liver tissue surrounding the tumor may lose hepatic function after high-dose irradiation. In this study, remnant functional liver volume (RFLV) was defined as the volume of liver tissue that retains normal function after irradiation, and the residual remnant functional liver volume after x Gy irradiation (rRFLV

methodsA total of 113 HCC patients who received stereotactic body radiotherapy (a SBRT group,

resultsAmong the 113 HCC patients, 12 were diagnosed with RILDs, including 11 in the IMRT group and only 1 in the SBRT group. Binary logistic regression with Hosmer-Lemeshow test results suggested that rRFLV

conclusionsEBRT is safe and effective for HCC patients at different stages. Compared with MLD and RLV, rRFLV

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsRadiosurgeryRadiotherapy, Intensity-ModulatedAgedFemaleHumansLiverMaleMiddle AgedRadiotherapy Dosagehepatocellular carcinomaradiotherapyreal-world studyremnant functional liver volumesafety

Identifiers

PMID41656812
PMCPMC12949857

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.